DESFLURANE LIQUID

국가: 캐나다

언어: 영어

출처: Health Canada

유효 성분:

DESFLURANE

제공처:

BLUE-ZONE TECHNOLOGIES LTD

ATC 코드:

N01AB07

INN (국제 이름):

DESFLURANE

복용량:

100%

약제 형태:

LIQUID

구성:

DESFLURANE 100%

관리 경로:

INHALATION

패키지 단위:

100

처방전 유형:

Prescription

치료 영역:

INHALATION ANESTHETICS

제품 요약:

Active ingredient group (AIG) number: 0128744001; AHFS:

승인 상태:

APPROVED

승인 날짜:

2020-04-17

제품 특성 요약

_ _
_DESFLURANE (desflurane, USP)_
_ _
_ _
_ _
_ _
_ _
_ _
_Page _
1
_ of _
47
_ _
PRODUCT MONOGRAPH
PR
DESFLURANE
(desflurane, USP) 100% v/v
Liquid for Inhalation
Inhalation Anesthetic
Blue-Zone Technologies Ltd.
Concord, ON
Canada L4K 3C1
Date of Preparation:
April 16, 2020
SUBMISSION CONTROL NO: 199804
_ _
_DESFLURANE (desflurane, USP)_
_ _
_ _
_ _
_ _
_ _
_ _
_Page _
2
_ of _
47
_ _
TABLE OF CONTENTS
PRODUCT MONOGRAPH
.........................................................................................................1
TABLE OF CONTENTS
..............................................................................................................2
PART I: HEALTH PROFESSIONAL INFORMATION
..........................................................3
SUMMARY PRODUCT INFORMATION
..........................................................................................................
3
INDICATIONS AND CLINICAL
USE.................................................................................................................
3
CONTRAINDICATIONS
......................................................................................................................................
4
WARNINGS AND PRECAUTIONS
.....................................................................................................................
4
ADVERSE REACTIONS
.....................................................................................................................................
11
DRUG INTERACTIONS
.....................................................................................................................................
16
DOSAGE AND ADMINISTRATION
.................................................................................................................
18
OVERDOSAGE
....................................................................................................................................................
21
ACTION AND CLINICAL PHARMACOLOGY
.......................................................